Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2021 | 3 |
2022 | 3 |
2023 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Hacking Pancreatic Cancer: Present and Future of Personalized Medicine.
Pharmaceuticals (Basel). 2021 Jul 15;14(7):677. doi: 10.3390/ph14070677.
Pharmaceuticals (Basel). 2021.
PMID: 34358103
Free PMC article.
Review.
Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma.
Rizzo A, Dalia Ricci A, Brandi G.
Rizzo A, et al. Among authors: dalia ricci a.
Oncologist. 2022 Dec 9;27(12):e976. doi: 10.1093/oncolo/oyac168.
Oncologist. 2022.
PMID: 35993601
Free PMC article.
Item in Clipboard
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.
Di Federico A, Mosca M, Pagani R, Carloni R, Frega G, De Giglio A, Rizzo A, Ricci D, Tavolari S, Di Marco M, Palloni A, Brandi G.
Di Federico A, et al. Among authors: ricci d.
Cancers (Basel). 2022 May 14;14(10):2429. doi: 10.3390/cancers14102429.
Cancers (Basel). 2022.
PMID: 35626033
Free PMC article.
Review.
Item in Clipboard
The evolution of biliary tract cancer: introducing a special focus issue from Immunotherapy.
Coyle L, Rizzo A, Ricci D.
Coyle L, et al. Among authors: ricci d.
Immunotherapy. 2023 May;15(7):471-472. doi: 10.2217/imt-2023-0074. Epub 2023 Apr 5.
Immunotherapy. 2023.
PMID: 37020402
No abstract available.
Item in Clipboard
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials.
Di Federico A, Rizzo A, Carloni R, De Giglio A, Bruno R, Ricci D, Brandi G.
Di Federico A, et al. Among authors: ricci d.
Expert Opin Investig Drugs. 2022 Apr;31(4):361-369. doi: 10.1080/13543784.2022.2009455. Epub 2021 Dec 1.
Expert Opin Investig Drugs. 2022.
PMID: 34798793
Item in Clipboard
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG, Calabrò D, Conci N, Argalia G, Marchese PV, Fabbri F, Fragomeno B, Ricci D, Fanti S, Ambrosini V, Ardizzoni A.
Dall'Olio FG, et al. Among authors: ricci d.
Eur J Cancer. 2021 Jun;150:99-107. doi: 10.1016/j.ejca.2021.03.020. Epub 2021 Apr 20.
Eur J Cancer. 2021.
PMID: 33892411
Item in Clipboard
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis.
Rizzo A, Nannini M, Novelli M, Dalia Ricci A, Scioscio VD, Pantaleo MA.
Rizzo A, et al. Among authors: dalia ricci a.
Ther Adv Med Oncol. 2020 Jul 7;12:1758835920936932. doi: 10.1177/1758835920936932. eCollection 2020.
Ther Adv Med Oncol. 2020.
PMID: 32684988
Free PMC article.
Item in Clipboard
Cite
Cite